In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

Introduction ADVERTISEMENT Peptides have become a focal point in research due to their intricate interactions with metabolic ...

Biomed Industries Unveils novel Quadruple Receptor Agonist for weight loss with Minimal Adverse Effects at the International Obesity conference in Las Vegas Dr. Lloyd L. Tran Biomed Industries, Inc.

Weight loss drugs have gained attention as a tool to help combat obesity, but understanding how they work, who they’re for, ...

Data from the US FDA's Adverse Event Reporting System on tirzepatide showed adverse events generally consistent with those ...

A new study explores the reasons why tirzepatide, the once-weekly injection used to treat obesity and type 2 diabetes, is ...

For significant weight loss, Zepbound may be the better option. If you have Type 2 diabetes and are looking for a dual ...

Global GLP-1 Analogues Market is valued at approximately USD 35.59 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 33% over the forecast period 2024-2032. Read the ...

Mazdutide also increased hepatic fatty acids oxidation via GCG receptor signalling and decreased HbA1c levels by 3.7mmol/mol ...

At "science day" in a Philly courthouse, both sides of a potentially ground-shifting legal case discussed how the diabetes ...

Natural supplements have “very mild effects” on weight loss based on what Dr. Ali has seen. There is some data to suggest ...